Therapies with weak, non-ionizing electromagnetic fields comprise FDA-approved
treatments such as Tumor Treating Fields (TTFields) that are used for adjuvant therapy of …

Simple Summary The FDA recently approved a fourth approach (in addition to surgery,
radiation therapy, and chemotherapy) for treating glioblastoma; namely, tumor treating fields …

Abstract Non‐thermal, intermediate frequency (100–500 kHz) electrotherapies present a
unique therapeutic strategy to treat malignant neoplasms. Here, pulsed electric fields (PEFs) …

Glioblastoma is the most common yet most lethal of primary brain cancers with a one-year
post-diagnosis survival rate of 65% and a five-year survival rate of barely 5%. Recently the …

Tumor treating fields (TTFields) represent a novel FDA-approved treatment modality for
patients with newly diagnosed or recurrent glioblastoma multiforme. This therapy applies …

Simple Summary Glioblastoma multiforme is an aggressive grade IV lethal brain tumour with
a median survival of 14 months. Despite surgery to remove the tumour, and subsequent …

Exposing cancer cells to alternating electric fields of 100-300 kHz frequency and 1-4 V/cm
strength has been shown to significantly reduce cancer growth in cell culture and in human …

Glioblastoma is a highly aggressive brain tumor, very invasive and thus difficult to eradicate
with standard oncology therapies. Bioelectric treatments based on pulsed electric fields …

While there is clear clinical evidence to support the therapeutic efficacy of low dose
alternating electric fields (TTFields) in treating glioblastoma, their intracellular targets and …

Simple Summary Glioblastoma is a rapidly progressing brain cancer that is very difficult to
treat. Given that many aspects of cell and tissue behavior are controlled by electric signaling …